Why VIVUS' Shares Spiked

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of anti-obesity drug maker VIVUS (Nasdaq: VVUS  ) shot higher by as much as 22% earlier in the trading session today following a decision by insurer Aetna (NYSE: AET  ) to begin providing coverage on Qsymia.

So what: In addition to Qsymia, Aetna also announced that it'd be covering Arena Pharmaceuticals' (Nasdaq: ARNA  ) Belviq when it finally makes it to pharmacy shelves. Thus far, VIVUS' Qsymia, which was seen as a potential blockbuster drug, has performed miserably, with roughly 30% of prescriptions left at pharmacies because patients have had to pay for the drug out of their own pockets, according to VIVUS' chief commercial officer, Mike Miller. Today's move should clear the way for some of those patients to begin to receive partial insurance coverage of Qsymia prescriptions and could cause other insurers to soon jump on board.

Now what: Before you get too excited, don't! Let's recall that every sales estimate out there has been blatantly inflated thus far, so it'd probably be wise to give Qsymia a quarter or two more before we make our final judgment as to whether or not it's being well accepted by physicians and patients. What we do know is that Arena's Belviq is in line to be the first internationally approved anti-obesity drug on the market, not VIVUS' Qsymia, and that Orexigen Therapeutics' (Nasdaq: OREX  ) Contrave is still years away from commercial production due to safety test delays and the need for further clinical trials. In short, Arena's currently in the driver's seat and everyone else is just along for the ride.

With a European approval now off the table for VIVUS, what's next for the fat-busting drug maker? Find out by getting your copy of our latest premium research report on VIVUS. Packed with in-depth analysis on the opportunities and threats facing VIVUS – and complete with a year of regular updates – this report will give you the tools needed to make smart long-term investing decisions. Click here to learn more.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 21, 2012, at 3:02 PM, SamFreedom wrote:

    Can't wait! There's going to be a hundred new articles by ppl w barely a high school level analysis and writibg skills just looking to pump up their name while misrepresenting ARENA all over again and again.

Add your comment.

DocumentId: 2123587, ~/Articles/ArticleHandler.aspx, 7/26/2014 7:10:54 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement